Alimera Sciences

PALADIN subset finds improvement after 12 months with intravitreal implantAmong a subset of patients in the phase IV PALADIN study, there was improved visual acuity, improved macular thickness, and reduced treatment burden among patients treated with the intravitreal fluocinolone acetonide 0.2 µg (Iluvien implant) for DME.
Partner Perspective: Patient Case Study - CONTINUOUS MICRODOSING™ TREATMENT WITH ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg
Phase IV study shows improved DME outcomes with fluocinolone acetonide implantThe fluocinolone acetonide 0.2 mcg/day implant (Iluvien, Alimera Sciences) offers an additional option for treating diabetic macular edema that reduces the need for subsequent therapy with anti-vascular endothelial growth factor or steroid treatment.
Time for a paradigm shift in the treatment of DMEWell tolerated and effective, anti-VEGF therapy is the current gold standard to treat DME. However, one treatment simply does not fit all and VEGF may just be one piece of a much larger puzzle. The fact that some DME patients have a limited response to anti-VEGF therapy is representative of this concept; we are discovering that there are additional inflammatory mediators that may be crucial components to the DME picture.
Real-world experience: Positive DME treatment outcomes observed with FAc implant at UK centreDr Mushtaq discusses one centre’s initial post-marketing experience with the fluocinolone acetonide intravitreal implant 0.19 mg. The implant demonstrated favourable outcomes and good patient acceptance.
Real-world experience: Case study shows maintained benefits with FAc in DME patientIn the case study discussed in this article, a patient who was treated for DME with a fluocinolone acetonide intravitreal implant reported improved vision-related quality of life and the ability to perform daily routines without problems. These benefits persisted 12-months after treatment.
FDA approves Iluvien for long-term treatment of DME; Alimera reactsThe FDA has approved Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.
Iluvien receives national marketing authorization in 10th countryThe Swedish Medical Products Agency has granted marketing authorization of Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Iluvien receives positive approval from 10 more countriesAlimera Sciences' sustained-release intravitreal implant (Iluvien)—its treatment of chronic macular edema—has received a positive outcome of the Repeat-Use Procedure with the Medicines and Healthcare products Regulatory Agency of the United Kingdom serving as the Reference Member State.
DME treatment gains marketing authorization in ItalyThe Italian Medicines Agency has granted marketing authorization to Alimera Sciences’ sustained-release intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema (DME).